SCHEMBL2194610

SCHEMBL2194610

Clc1ccc(CN(I)I)cc1.Cn1nc(-c2ccccc2)[nH]c1=[Pt]

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.37
LMNA P02545 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
MAPT P10636 1/20 0.36
STAT3 P40763 1/20 0.36
NR1H2 P55055 1/20 0.36
NR1H3 Q13133 1/20 0.36
CXCR2 P25025 1/20 0.36
SCN2A Q99250 1/20 0.35
LCK P06239 1/20 0.34
FYN P06241 1/20 0.34
LYN P07948 1/20 0.34
PIM1 P11309 1/20 0.34
SRC P12931 1/20 0.34
FLT4 P35916 1/20 0.34
FLT3 P36888 1/20 0.34
BLK P51451 1/20 0.34
AURKB Q96GD4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2197165 0.91 CSF1R (0.38) LMNAMAPTCXCR2CSF1R
SCHEMBL2193790 0.89 CYP19A1 (0.38) CYP19A1LMNASMN1; SMN2KMT2AMEN1
SCHEMBL2193102 0.88 ALOX5 (0.40) CYP19A1LMNASMN1; SMN2KMT2AMEN1
SCHEMBL2193608 0.88 MAPK13 (0.36) MAPTNR1H2NR1H3MAPK13MAPK12
SCHEMBL2195584 0.85 CXCR2 (0.38) CYP19A1KMT2AMEN1CXCR2SCN2A
SCHEMBL2192771 0.84 LMNA (0.33) LMNAKMT2AMEN1CSF1R
SCHEMBL2196817 0.82 NR1H2 (0.36) SMN1; SMN2MAPTNR1H2NR1H3
SCHEMBL2196159 0.75 CYP19A1 (0.39) CYP19A1LMNASMN1; SMN2KMT2AMEN1
SCHEMBL2193146 0.74 LSS (0.38) SMN1; SMN2KMT2AMEN1PDE4DPDE7A
SCHEMBL2195930 0.74 GAA (0.34) SMN1; SMN2KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8980875-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-03-17 US claimed
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-12-19 US claimed
US-8481522-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-07-09 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 CYP19A1 787/4885LMNA 2301/4885SMN1; SMN2 4069/4885
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 CYP19A1 787/4885LMNA 2301/4885SMN1; SMN2 4069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.